预测多发性硬化症 (POINT-MS) 最佳个性化治疗反应的单中心,前性队列:一个队列概况
Ronja Christensen1, Alessandro Cruciani2,3,4, Sarmad Al-Araji2
1UCL Queen Square Institute of Neurology, UCL, London, UK ronja.christensen@ucl.ac.uk.
BMJ open
|September 25, 2025
概括
预测MS最佳个性化治疗反应 (POINT-MS) 研究收集了748名开始疾病修饰治疗 (DMT) 的患者的基线数据. 这项研究旨在开发一种基于综合患者数据的个性化MS治疗选择工具.
科学领域:
- 神经学 神经学
- 生物标志物研究 生物标志物研究
- 临床试验 临床试验
背景情况:
- 多发性硬化症 (MS) 影响英国15万人,构成严重的医疗保健挑战.
- 改变疾病的治疗 (DMT) 对于治疗多发性硬化症至关重要,但患者的反应差异很大.
- 在MS中预测最佳个性化治疗反应 (POINT-MS) 队列是为了解决这种变异性而建立的.
研究的目的:
- 介绍POINT-MS队列的基线特征和研究设计.
- 为未来的分析奠定基础,旨在预测MS的个体治疗反应.
- 整合临床,成像,血清和遗传数据,以进行个性化治疗预测.
主要方法:
- 建立了781名成年多发性硬化患者的前性观察队列和生物库.
- 参与者接受了全面的评估,包括临床评估,MRI,OCT和多个时间点的血液测试.
- 数据收集的重点是DMT开始后3个月内的基线特征.
主要成果:
- 从748名参与者的基线数据显示,主要是白人队列,患有复发性复发性多发性硬化症的女性患者,平均年龄为40.8岁.
- 尽管残疾分数低 (EDSS中位数为2.0),但40%的人表现出认知障碍,98.4%的人患有并发症.
- 与健康对照人群相比,基线MRI在26% (大脑) 和8.5% (脊髓) 发现了新的病变,灰色和白色物质体积和上脊髓横截面积减少.
结论:
- POINT-MS队列为了解治疗开始时的MS异质性提供了丰富的数据集.
- 基线特征突出显示了认知障碍和并发症的存在,即使在早期的MS.
- 未来的分析将利用这些数据开发个性化DMT选择的预测模型.
更多相关视频
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
2.3K
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.7K
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Bioavailability Study Design: Single Versus Multiple Dose Studies
210
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
210
